Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer
– This submission is supported by the pivotal Phase 3 VERITAC-2 clinical trial, results of which were recently presented at the 2025 American Society for Clinical Oncology Annual Meeting and published in The New England Journal of Medicine –
– VERITAC-2 data support vepdegestrant as a potential treatment option in patients with ESR1m ER+/HER2- advanced or metastatic breast cancer –
NEW HAVEN, Conn., June 06, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) with its partner Pfizer Inc. (NYSE: PFE), for vepdegestrant for the treatment of patients with ER-positive (ER+)/human epidermal growth factor receptor 2 (HER2)-negative (ER+/HER2-) ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy. This submission is based on results from VERITAC-2 (NCT05654623), a global, randomized Phase 3 trial evaluating vepdegestrant versus fulvestrant.
'This milestone comes after an exciting presentation at the American Society of Clinical Oncology's annual meeting,' said John Houston, Ph.D., Chairperson, Chief Executive Officer and President at Arvinas. 'We look forward to the NDA review and to the first ever FDA-approved PROTAC ER degrader potentially being available to patients who could benefit from a much needed, new treatment option.'
Vepdegestrant is being jointly developed by Arvinas and Pfizer for the treatment of patients with advanced or metastatic ER+/HER2- breast cancer and was granted fast track designation as a monotherapy by the FDA. Results from the VERITAC-2 study were recently presented in a late-breaking oral presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting and were selected for the ASCO press briefing and for Best of ASCO. Detailed results were also simultaneously published in the New England Journal of Medicine.
About the VERITAC-2 Clinical Trial
The Phase 3 VERITAC-2 clinical trial ( NCT05654623 ) is a global, randomized trial evaluating the efficacy and safety of vepdegestrant (ARV-471) as a monotherapy compared to fulvestrant in patients with ER+/HER2- advanced or metastatic breast cancer. The trial enrolled 624 patients at sites in 25 countries who had previously received treatment with a CDK4/6 inhibitor plus endocrine therapy.
Patients were randomized 1:1 to receive either vepdegestrant once daily, orally on a 28-day continuous dosing schedule, or fulvestrant, administered intramuscularly on Days 1 and 15 of Cycle 1 and then on Day 1 of each 28-day cycle starting from Day 1 of Cycle 2. In the trial, 43% of patients (n=270) had ESR1 mutations detected. The primary endpoint was progression-free survival (PFS) in the ESR1-mutation and intent-to-treat populations as determined by blinded independent central review. Overall survival is the key secondary endpoint.
About Vepdegestrant
Vepdegestrant is an investigational, orally bioavailable PROTAC (PROteolysis TArgeting Chimera) protein degrader designed to specifically target and degrade the estrogen receptor (ER). Vepdegestrant is being developed as a potential monotherapy for ER+/HER2- advanced or metastatic breast cancer with estrogen receptor 1 (ESR1) mutations in the second line-plus setting.
In July 2021, Arvinas announced a global collaboration with Pfizer for the co-development and co-commercialization of vepdegestrant; Arvinas and Pfizer will share worldwide development costs, commercialization expenses, and profits.
The U.S. Food and Drug Administration (FDA) has granted vepdegestrant Fast Track designation as a monotherapy in the treatment of adults with ER+/HER2- advanced or metastatic breast cancer previously treated with endocrine-based therapy.
About Arvinas
Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body's natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and ARV-102, targeting LRRK2 for neurodegenerative disorders. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding: the NDA review and to the first ever FDA-approved PROTAC ER degrader potentially being available to patients who could benefit from a much needed, new treatment option; and vepdegestrant's development as a potential monotherapy for ER+/HER2- advanced or metastatic breast cancer with ESR1 mutations in the second line-plus setting. All statements, other than statements of historical fact, contained in this press release, including statements regarding Arvinas' strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words 'anticipate,' 'believe,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'target,' 'goal,' 'potential,' 'will,' 'would,' 'could,' 'should,' 'look forward,' 'continue,' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
Arvinas may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Arvinas makes as a result of various risks and uncertainties, including but not limited to: whether Arvinas and Pfizer will successfully perform their respective obligations under the collaboration between Arvinas and Pfizer; whether Arvinas and Pfizer will be able to successfully conduct and complete clinical development for vepdegestrant as a monotherapy; whether the VERITAC-2 clinical trial will meet the secondary endpoint for overall survival; risks related to our expectations regarding the potential clinical benefit of vepdegestrant to patients; uncertainties relating to regulatory applications and related filing and approval timelines, including the New Drug Application seeking FDA approval of vepdegestrant and the risk that any regulatory approvals, if granted, may be subject to significant limitations on use or subject to withdrawal or other adverse actions by the applicable regulatory authority; whether FDA or other regulatory authorities will require additional information or further studies, or may fail or refuse to approve or may delay approval of vepdegestrant; whether Arvinas and Pfizer, as appropriate, will be able to obtain marketing approval for and commercialize vepdegestrant and other product candidates on current timelines or at all; Arvinas' ability to protect its intellectual property portfolio; Arvinas' reliance on third parties; whether Arvinas will be able to raise capital when needed; whether Arvinas' cash and cash equivalent resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; and other important factors discussed in the 'Risk Factors' section of Arvinas' Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent other reports on file with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this press release reflect Arvinas' current views with respect to future events, and Arvinas assumes no obligation to update any forward-looking statements, except as required by applicable law. These forward-looking statements should not be relied upon as representing Arvinas' views as of any date subsequent to the date of this release.
Contacts
Investors:
Jeff Boyle
+1 (347) 247-5089
[email protected]
Media:
Kirsten Owens
+1 (203) 584-0307
[email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
42 minutes ago
- Yahoo
Trump signs new executive orders intended to make flying cars a reality, slash flight times
President Donald Trump signed three new executive orders Friday aimed at accelerating American drone innovation and supersonic air travel, while also restoring security to American airspace. The three orders will be critical to American safety and security, White House officials involved in the drafting of the orders indicated, particularly in light of major worldwide events coming to the United States in the next few years, such as the World Cup and the Olympics. In addition to bolstering safety and security, the new orders will also spur greater innovation in the aerospace and drone sectors, something White House officials said has been stifled in recent years as a result of burdensome regulations. "Flying cars are not just for the Jetsons," Michael Kratsios, a lead tech policy advisor at the White House said. "Since the beginning of his first term, President Trump has recognized the incredible potential of drones to boost American productivity, create high-skilled jobs and meet national needs in areas like public safety, infrastructure, inspection, agriculture and more. But, for too long, red tape has hindered homegrown drone innovation, restricting commercial drone use and burdening their development." Duffy Contrasts Biden-era 'Drone Fiasco' With Trump Admin's 'Radical Transparency' After Faa Announces Testing Kratsios said the same about supersonic aviation, noting "Americans should be able to fly from New York to LA in under four hours." Read On The Fox News App Besides promoting innovation, the orders seek to shore up American airspace sovereignty. This directive is aimed at not only addressing potentially criminal or terror-related threats. It also aims to increase penalties for and reduce the prevalence of drone misuse in American airspace. "The president week one wanted us to take this issue seriously because of the national fury over the events over New Jersey," Sebastian Gorka, senior director of counterterrorism on the Trump administration's National Security Council, said of the new executive orders signed Friday. "For far too many years, we have not had a requisite, necessary federal response — not only to the dominance of non-U.S. platforms in this field, but also protecting sensitive sites, military sites, critical infrastructure, but also just sporting events, mass events." Rebecca Grant: America Has A Drone Problem, And No One Is In Charge White House officials who advised the president on these new executive orders said there will be more protection for critical infrastructure for sporting venues as a result of the new directives, including the upcoming FIFA World Cup. They will also enable "routine beyond visual line of sight commercial operations," such as drone deliveries, infrastructure maintenance and emergency response to incidents like wildfires. The orders will also reduce the United States' reliance on foreign countries for drone and other aviation technology, officials added. "These executive orders will accelerate American innovation in drones, flying cars and supersonic aircraft and chart the future of America's skies for years to come," Kratsios said. "Our message is simple. American innovation belongs in American aerospace."Original article source: Trump signs new executive orders intended to make flying cars a reality, slash flight times
Yahoo
42 minutes ago
- Yahoo
Elon Musk's crash-out killed conservatives' momentum — and likely guaranteed passage of Trump's ‘big beautiful bill'
Earlier this week, it looked like Elon Musk had delivered arch conservatives a gift when he trashed President Donald Trump's 'One Big, Beautiful Bill.' On Tuesday, Musk called the legislation an 'outrageous, pork-filled, disgusting abomination.' It seemed like a boon for some of the fiscal conservatives in the Senate like Sens. Rand Paul of Kentucky and Ron Johnson of Wisconsin who criticized the fact the bill still blows up the deficit. Had Musk stopped there, he probably would have given fiscal conservatives additional leverage. House Speaker Mike Johnson had spent much of the first part of the year getting every faction of the House GOP on board with the bill despite fiscal conservative grumbling. But Johnson admitted during his weekly press conference that he had tried to call Musk with no response. Immediately, House Republicans and members of the Freedom Caucus — including its former chairman Scott Perry and Andy Ogles, who has tried to allow Trump to run for a third term — voiced their criticisms of the bill that they had when it was being deliberated. They could have voiced them at any moment but did not. It clearly showed that they had abandoned their fiscal conservative principles in fear of the pressure campaign from Trump. Had Musk kept his critiques strictly to the bill, the tech tycoon could have offered an effective counterweight to give conservatives leverage against leadership given his immense wealth and his wide reach as owner of X. But the world's richest man chose to blow that to smithereens when he turned the attacks personal. First, he said that Trump would not have won the presidency, Republicans would have lost the House and would have a smaller minority in the Senate had it not been for Musk's money, before huffing 'such ingratitude.' Then Musk lobbed the ultimate grenade when he said that Trump had not fully released the 'Epstein files' —information related to the late financier who parlayed his money into sex trafficking teenaged girls — because Trump was mentioned in them. The Tesla founder took it a step further by calling for Trump's impeachment. Not only did Musk's words permanently spike any chance for reconciliation, it killed any chances for budget reconciliation, the arcane process through which Republicans hope to pass the 'One Big, Beautiful Bill.' Rep. Chip Roy of Texas, who has spent much of the legislative process in the House trying to make the bill more conservative but ultimately voted for it, tried to split the difference. 'He's got concerns with the bill, he's a free American, and he can speak freely and and God bless him for what he's been doing to try to make improvements,' Roy told The Independent. 'Again, is it what Chip Roy would draft? Not even close. But did it move in the right direction to get to a place that I felt comfortable sending it to the Senate to see if they could make it better? Sure.' Rep. Anna Paulina Luna, who has spent much of the new Congress trying to declassify information related to Epstein, said it was too early to tell about the Senate bill since text did not exist. 'I've always been a big fan of going back to pre-Covid spending levels,' Luna told The Independent, but understood it would require negotiation. Rep. Andy Harris, the chairman of the House Freedom Caucus, who ultimately voted 'present' on the bill last month, said he agreed. 'I still think his concerns about the deficit are real,' he said. But the damage might already be done. If Republican elected have learned anything in the past decade, they've learned that their voters are not so much devoted to conservative ideals; they're devoted to Trump. Deviation from Trump, even in the name of conservative principles like restraining spending and balanced budgets, amounts to heresy. Musk's decision to start talking about forming another political party further alienates him from the GOP. He is now no longer part of the Trump coalition or even the Republican coalition. That means that fiscal conservatives cannot depend on him to drop millions of dollars for people opposed to the reconciliation bill or if he does, that it will immediately be tainted as money coming from a heretic. This makes Senate and House leadership's job easier. It gives them a foil to oppose and allows critics of the bill to tied to Musk. And they've already seen that most Republicans' bluster about spending levels are just that given that they will ultimately fold. Rep. Tim Burchett of Tennessee spent much of the early parts of the reconciliation process intimating to reporters that he would not vote for the bill only to fold. As votes wrapped on Thursday, he did not seem worried about it all. 'It's just two biggest dogs in the pound, they're both gonna fight a little,' he said. Except now, Musk just defanged fiscal conservatives.
Yahoo
an hour ago
- Yahoo
US and Chinese officials will resume trade talks in London on Monday, Trump says
President Donald Trump announced Friday that US and Chinese officials will meet in London on Monday to discuss trade between the two nations. 'I am pleased to announce that Secretary of the Treasury Scott Bessent, Secretary of Commerce Howard Lutnick, and United States Trade Representative, Ambassador Jamieson Greer, will be meeting in London on Monday, June 9, 2025, with Representatives of China, with reference to the Trade Deal,' the president wrote in a post on Truth Social. The announcement comes after Trump and his Chinese counterpart Xi Jinping spoke for 90 minutes on Thursday. After the phone call, the US president said he was encouraged that ongoing trade tensions could soon be resolved. The last talks between the Trump administration and their Chinese counterparts, held on May 12 in Geneva, represented a major turning point for the global trade war. Delegates from China and the United States announced they would significantly roll back their historically high tariffs on one another. Markets rallied, Wall Street banks curtailed their recession forecasts, and moribund USconsumer confidence rebounded significantly. That marked a significant change from April, when tensions ran so high that trade between the United States and China came to an effective halt. The 145% tariffs on most Chinese imported goods made the math impossible for American businesses to buy virtually anything from China, America's second-largest trading partner. But since then, tensions had re-escalated. Trump on Wednesday said in a Truth Social post that Chinese leader Xi Jinping was 'extremely hard to make a deal with.' Trade talks have stalled, Bessent said, apparently frustrating Trump. Last week, Trump posted on social media that China 'TOTALLY VIOLATED ITS AGREEMENT WITH US.' Trump said that he made a 'fast deal' with China to 'save them from what I thought was going to be a very bad situation.' He added: 'So much for being Mr. NICE GUY!' The Trump administration had expected China to lift restrictions on rare earth materials that are critical components for a wide range of electronics, but China has largely refused, causing intense displeasure inside the Trump administration and prompting a recent series of measures to be imposed on the country three administration officials told CNN last week. For example, the White House warned US companies against using AI chips made by China's national tech champion Huawei. It stopped US companies from selling to China software that is used to design semiconductors. And the US State Department announced it would 'aggressively revoke visas' for some Chinese students in in turn, has accused the United States of 'provoking new economic and trade frictions.' 'The United States has been unilaterally provoking new economic and trade frictions, exacerbating the uncertainty and instability of bilateral economic and trade relations,' the Chinese Commerce Ministry said Sunday. In the meantime, Treasury Secretary Scott Bessent, America's chief negotiator in the détente with China, said talks with China had stalled. But Trump and and Chinese leader Xi Jinping held a long-awaited phone call Thursday, which appears to have lowered the temperature a bit. The New York Times on Friday reported China has issued some licenses for rare earths, although the market is hardly back open. The talks in the UK are significant, and much is riding on their success – US economic growth remains steady but there are signs of cracking. And no one wants to return to April's standoff, which threatened to plunge the global economy into a stocks, which had rallied earlier in the day on a strong jobs report, rose a bit higher after Trump's Truth Social message about the resumed talks. The Dow was up 450 points, or 1.1%. The S&P 500 rose 1.2%, and the Nasdaq was 1.3% higher.
